Background: While 12% of low/intermediate-risk stable chest pain patients are inappropriately discharged, 25% are unnecessarily readmitted. Overall 30% of these patients diagnosed as noncardiac chest pain have a cardiac event within 1-2 years and subsequently die from cardiovascular (CV) disease or have an acute coronary syndrome (ACS) during 5 years. The analysis shows that this subgroup patients benefit from intervention. The objectives, hypothesis, questions, and issues mentioned addressed and answered by the arms and substudies of the PROMISE trial include the following:
Objectives: The objective of the study is to determine whether an initial noninvasive anatomic imaging strategy with CTCA will improve clinical outcomes in subjects with symptoms concerning for coronary artery disease (CAD) relative to an initial functional testing (FT) strategy (usual care).
To compare core laboratory interpretation (CLI) versus
local site laboratory interpretation (SLI) for significant CAD and major adverse CV events (MACE) 2. To compare and contrast the economics of anatomical versus functional diagnostic testing for obstructive CAD in patients with stable chest pain.
Hypotheses:
1. Absolute concentration of high-sensitivity troponin I (hsTnI) may relate to the degree and extent of obstructive CAD 2. Absolute hsTnI concentrations may be useful to triage downstream testing based on risk as opposed to the degree and extent of obstructive CAD.
Questions:
1. What is the association between high-risk plaque (HRP) and MACE? Methods: Pragmatic randomized trial of the clinical effectiveness of diagnostic testing strategies for CA) was performed in outpatient settings including acute and primary care and cardiology offices. Qualifying patients presenting with new or worsening symptoms suspicious for clinically significant CAD who require diagnostic testing and have not been previously evaluated were randomized to an initial strategy of either anatomic or FT. The clinical care team was responsible for all decisions regarding additional testing, medications and/or procedures. Within the FT arm, the subject's care team selected the specific test to be performed (exercise electrocardiogram, stress nuclear, or stress echocardiogram) consistent with "usual care" in that practice setting.
Outcomes: As the sensitivity of CTCA is more than FT and the specificity of FT is more than CTCA the overall discriminatory abilities of both tests were similar [ Table 8 ] 10. Complications were negligibly rare for both CTCA and FT. CTCA detected more incidental findings. CTCA radiation dose is less than nuclear stress testing and is independent of patient characteristics [ Table 9 ].
CTCA is superior to FT strategies in prognostication, risk stratification of stable chest pain patients with low/intermediate pretest probability for obstructive CAD. In addition, CTCA can estimate CAC as well as HRP. DM has a negligible effect on the pretest probability of obstructive CAD.
What is inferable is that the integration of SLI and CLI should improve the sensitivity and specificity of CTCA in the evaluation of stable chest pain with low and intermediate pretest probability for obstructive CAD. This can be achieved through seamless cooperation between the two laboratories by real-time sharing of imaging data. Interestingly, the same may be extrapolated to other functional imaging strategies (exercise electrocardiogram, stress echocardiogram, and nuclear stress test), and similar benefits may be expected.
In a nutshell, every diagnostic strategy has its own pros and cons. The modest exercise electrocardiogram, workhorse stress echocardiogram, erudite nuclear stress test, sophisticated CTCA, and naive circulating biomarkers all have a complementary and respectable role to play in risk stratification, management, and prognostication in stable chest pain with intermediate pretest probability for obstructive CAD. To this repertoire of functional, anatomical, and biochemical strategies, the addition of metabolic strategies in the form of positron-emission tomography (PET), PET with CT completes the ideal diagnostic armamentarium for stable chest pain syndromes with intermediate pretest probability for obstructive CAD. 
Trial Summary
Introduction: The magical utility of CTCA is that it performs two tests in one session-measure CAC scores and performs coronary angiography (CAG). CAC score is an independent risk factor for obstructive CAD. Even low-CAC scores correlate with the doubling of coronary events. The relative risk associated with CAC scores is greater than that associated with established factors, such as smoking, hypertension, and diabetes mellitus. Interestingly, the relative risk of smoking, hypertension, and DM for obstructive CAD is significantly less than that of CAC score. The presence of CAC can be used as a surrogate marker for atheromatous plaque disease and its progression as a marker for CV event rates. It cannot be used as a surrogate marker for soft plaque, presence of obstructive atheroma, measure of luminal stenosis, or patient's response to medical interventions.
Background: Very often patients with low/intermediate-risk stable chest pain with obstructive CAD are underdiagnosed, misdiagnosed, or overdiagnosed. Rapid access outpatient chest pain clinics are like "one-stop centers" for accurate diagnosis and risk stratification of such patients with stable chest pain. CTCA has a sensitivity of 89% and specificity of 96% for the detection of CAD with obesity, coronary calcification, or arrhythmia, radiation exposure being the limiting factors. Advances in scanning technology are paving way for improved spatial and temporal resolution with lower radiation doses. 1. High-sensitivity cardiac troponin (cTn) I can improve the estimation of the pretest probability for obstructive CAD in patients with stable chest pain. Inclusion Criteria: Patients between the ages of 18-75 years as well as those attending Rapid Access Chest Pain Clinics were included in the study. Exclusion Criteria: Morbid obesity, patient refusing to undergo CTCA or unable to give informed consent, serum creatinine >200 µmol/L, estimated glomerular filtration rate <30 mL/min, previous recruitment to the trial, allergy to iodinated contrast agent, pregnancy, recent ACS.
Objectives

Results:
The SCOT-HEART multicenter randomized controlled trial is a positive trial. Most of the results may be considered by standing committee members to be embedded into recommendations and guidelines.
Conclusion:
In patients with low/intermediate-risk stable chest pain due to obstructive CAD, CTCA assists the diagnosis and leads to major additive value in planning further diagnostics and managing therapies leading to reduction in MACE. Further long-term randomized clinical trials (RCTs) are warranted to prove that these benefits are reflected in the long-term outcomes also.
Clinical Perspective
What is already known: Rapid access chest pain clinics have facilitated the early diagnosis and management of patients with low/intermediate-risk stable chest pain and obstructive CAD. However, CAD continues to be under-diagnosed, misdiagnosed, and over diagnosed leading to patients being undertreated, maltreated, and overtreated, respectively.
What is not known: Implications for the management of low and intermediate pretest probability low/intermediate-risk stable chest pain patients due to outcome-focused systematic implementation of CTCA in the patient care pathway of rapid chest pain clinics.
Insights from SCOT-HEART Trial:
1. Adverse coronary plaque characteristics and overall calcified plaque burden increase MACE [ Table 10 ] 2. The PROMISE minimal-risk tool outperforms the CAD Consortium model with regards to prognostic discrimination in patients with suspected stable angina and may assist clinicians in decisions regarding noninvasive testing [Table 11 ] 3. High-sensitivity cTn I concentration is an independent predictor of obstructive CAD in patients with stable chest pain [ Table 12 ] 4. CTCA resulted in a significantly lower MACE (death from coronary heart disease or nonfatal MI) at 5 years than standard care alone, without resulting in a significantly higher rate of coronary angiography or coronary revascularization [ Veldkamp RF, Ten Haaf ME, et al. Effect of using the HEART score in patients with chest pain in the emergency department: A Stepped-wedge, cluster randomized trial. Ann Intern Med 2017;166:689-97.
Trial Summary
Objective: The objective is to quantify the impact of the use of the history, electrocardiogram, age, risk factors, and initial troponin risk score on patient outcomes, costs, in patients with chest pain presenting at the emergency room, as well as compare its performance with that of the thrombolysis in MI (TIMI) and Global Registry of Acute Coronary Events (GRACE) Scores.
Background: About 6.3% of patients visiting the emergency department (ED) with a complaint of chest pain. Rapid accurate diagnosis is envisaged. Inability to diagnose and manage ACS optimally can have a negative impact on their prognosis.
Hypothesis:
The heart score is a useful tool to stratify patients with chest pain according to their short-term risk for MACE. Primary Endpoint: The occurrence of MACE (i.e., CTCA group >standard-care group SCOT-HEART Trial=Scottish COmputed Tomography of the HEART trial, HR=Hazard ratio, P=Probability, CI=Confidence interval, CTCA=Computed tomographic coronary angiography, AMI=Acute myocardial infarction SCOT-HEART Trial=Scottish computed tomography of the HEART trial, CTCA=Computed tomographic coronary angiography, hsTnI=High-sensitivity troponin I, ACC=American College of Cardiology, AHA=American Heart Association, CAD=Coronary artery disease, CI=Confidence interval AMI, percutaneous coronary intervention, coronary artery bypass grafting, or death) within 6 weeks after presentation. Secondary Endpoint: QOL, costs of heart score, and cost-effectiveness of heart score as compared to usual care in different patient populations, pre-specified subgroup analyses were performed according to age (below and above 62 years of age), gender (men vs. women), disease (diabetics vs. non-diabetics), and ethnicity (caucasian vs. noncaucasian).
Methods:
The HEART impact trial is a randomized, both parallel as well as crossover assignment, stepped wedge, SCOT-HEART trial=Scottish COmputed Tomography of the HEART trial, R=Randomization, CTCA=Computed tomographic coronary angiography, CI=Confidence interval, SD=Standard deviation, MACE=Major adverse cardiovascular events, HR=Hazard ratio, FT=Functional testing, CAC=Coronary artery calcium, CAD=Coronary artery disease, MI=Myocardial infarction, P=Probability, RR=Relative risk, AP=Angina pectoris, n=Sample size, RR=Relative risk cluster, and diagnostic purpose trial. Hospitals applied "usual care" or the HEART score to patients as per the trial protocol over a period of 14 months. Inclusion Criteria: All patients presenting with chest pain to the cardiac ED older than 18 years. Exclusion Criteria: Children (age <18 years), inability to fill in questionnaires, inability to give consent.
Results:
There was no significant difference in the incidence of MACE in subgroup analyses according to age (below and above 62 years of age), gender (men vs. women), disease (diabetics vs. nondiabetics), and ethnicity (caucasian vs. noncaucasian).
Conclusions:
The HEART impact trial proves that HEART score is superior to the GRACE and TIMI scores in risk stratification and prognostication. The HEART score stratified patients with and without MACE as well as identified the low-risk patients at more efficiently than the GRACE and TIMI scores at the same level of safety.
Clinical Perspective
Unfortunately, even patients with low and intermediate pretest risk probability for ACS are hospitalized and extensively evaluated with noninvasive stress testing or an invasive coronary angiography. Early recognition of patients at low risk for ACS transmogrifies into diminished patient burden, diagnostic testing, length of stay, frequency of hospitalization, and associated expense.
What is known: The utility of TIMI score, GRACE score, HEART score in risk stratification of patients with low/ intermediate-risk stable chest pain with low pretest probability of ACS.
What is not known: It is unclear which of the three risk scoring systems is superior and performs best in identifying patients at "low risk" of ACS, as these patients are candidates for early discharge from the ED.
Insights from HEART impact trial: Head-to-head comparison of the GRACE, HEART, and TIMI score was done in a large prospective cohort of chest pain patients. The HEART score performed best in discriminating between those with and without MACE. The HEART score identified the largest number of patients (40.5%) as low risk without compromising safety. The results justify the routine usage of HEART score in the risk stratification and prognostication of patients with low/ intermediate-risk stable chest pain in the ED [Tables 19 and 20 
Trial Summary
Introduction: Chest pain is the second most common reason patients visit EDs. Even very low-risk patients are often admitted for prolonged observation and unnecessary advanced cardiac testing.
Hypothesis:
The use of the decision aid will significantly increase patient knowledge, engagement, and satisfaction, and decrease the rate of testing that may have marginal benefit in the low-risk population with no increase in MACE.
Background: Decision-making, the patient education regarding their 45-day risk for ACS and management options, has the potential to safely decrease health-care utilization.
Objective:
The objective is to test the effectiveness of the Chest Pain Choice (CPC) decision aid on health-care utilization within 30 days after enrolment to safely improve validate patient-centered outcome measures as well as promote evidence-based patient-centered evaluation in a pragmatic, parallel, and RCT.
Methods: CPC trial investigators randomized 898 patients in an interventional, parallel assignment, double-masked study. The clinician reviewed the decision aid, educated the patient Low-risk patients MACEs 2.0% (95% CI -1.2%-3.3%) HEART impact trial=Impact on Management of the HEART Risk Score in Chest Pain Patients trial, MACE=Major adverse cardiovascular events, HR=Hazard ratio. P=Probability, n=sample size regarding their individual risk for a heart attack or preheart attack as well as provided the patient with management options consistent with both the patient's values and preferences. Inclusion Criteria: Patients more than 18 years of age with chest pain were admitted to ED for cardiac testing. Exclusion criteria: Ischemic changes on the electrocardiogram, elevated cTn, potential ACS, cocaine use within the previous 72 h, pregnancy, patients undergoing medical clearance in a detox center, involuntary court or magistrate order, homelessness, out-of-town residence, patients in police custody, incarcerated individuals, major communication barriers that would compromise their ability to give written informed consent. Primary outcome: Test if CPC safely improves patient knowledge. Secondary outcome: Test if the decision aid has an effect on health care, safely improves patient engagement.
Results: Adverse coronary plaque characteristics, increased calcified plaque burden, and high-sensitivity cTn I concentration are independent predictors of obstructive CAD and lead to increased MACE. CTCA plus standard care resulted in lower MACE at 5 years than standard care alone without significant change in the number of CAG/coronary revascularization in the group.
Conclusion: Decision aid increases patient knowledge about their risk and safely decreases the rate of admissions. Patients can be engaged in optimally shared decision-making in a way that is acceptable to patients, clinicians, and policymakers [ Table 20 ].
Clinical Perspective
Shared decision-making, educating patients regarding their 45-day risk for ACS and management options, might safely decrease unnecessary health-care utilization.
What is known: a. Utility of decision aid in health-care utilization.
What is not known: a. Effectiveness, safety, and acceptability of a shared decision-making approach to communicate risk to patients and engage them in decisions about testing and follow-up b. Decision aid versus usual care in further outpatient evaluation and management of patients with possible ACS c. Effectiveness of a decision aid on patient-centered outcomes and safety in low-risk chest pain patients from diverse geographic and ethnic backgrounds.
Insights from the CPC trial:
a. Decision aid increases patient knowledge about their risk [ Table 21 ] b. Decision aid increases patient involvement and safely decreases the rate of admissions [Table 21 ] c. Patients can be engaged in optimally shared decision-making in a way that is acceptable to patients, clinicians, and policymakers [ Table 21 ].
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